Collagen supplement may turn back the clock on aging cells

NCT ID NCT07456449

First seen Mar 11, 2026 · Last updated Jun 23, 2026 · Updated 17 times

Summary

This study tests whether taking collagen peptides daily for 6 months can help slow aging at the cellular level in adults aged 50-70 who are overweight and not very active. Researchers will measure telomere length (a marker of cellular age), inflammation, and body composition. 125 participants will be randomly assigned to take either collagen or a placebo, with blood tests and physical assessments at the start, 3 months, and 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY AGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Vienna, NuTraLab

    RECRUITING

    Vienna, State of Vienna, 1070, Austria

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

collagen peptides

What this could lead to

If it works, this could point toward a simple dietary supplement that supports healthier aging at the cellular level.

What could go wrong

This is an early-stage, small study (125 people) testing a supplement, not a drug. Results may show no effect on telomeres or aging markers, and any benefits may not apply to the general population.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.